Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma "Safety profile is one of the real advantages" of non-covalent BTK inhibitor, says panelist Jan 11, 2024 video
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question Jan 11, 2024 video
Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study Jan 04, 2024 video
Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma Study results show impressive efficacy, favorable safety profile in the second line Jan 04, 2024 video
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL Approach could allow for a response-adapted reduction of CHOP Dec 27, 2023 video
Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma Our panel of experts discuss 3-year findings from the phase II ELARA study Dec 26, 2023 video
Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years Bispecific antibody also shows high response rates in frontline setting Dec 20, 2023 video
Positive Results for Odronextamab in Relapsed/Refractory DLBCL But experts aren't sure where it would fit in with currently approved bispecifics Dec 20, 2023 video
JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
Rituximab Maintenance Boosts Survival for Older Adults With MRD-Negative MCL Patients with treatment-sensitive disease may benefit most from continued treatment, says expert Dec 05, 2023
Charting the Course: From Young Adult Leukemia Patient to Oncologist My experience shaped how I care for patients today Dec 03, 2023
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL However, it may benefit children at increased risk of thrombosis Nov 20, 2023
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent' No easy answers for two drugs for rare lymphoma on long cruise with accelerated approval Nov 16, 2023
Lymphoma Drug Copanlisib to Be Pulled From U.S. Market Failed confirmatory trial takes down another PI3K inhibitor Nov 14, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening News, features, and commentary about cancer-related issues Sep 28, 2023
Weight-Loss Surgery Tied to Lower Blood Cancer Risk in Women Consider surgery for primary prevention in people with obesity, researchers suggest Sep 15, 2023
High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody Response rate exceeds 60%, with 15- to 20-month duration with epcoritamab Sep 11, 2023
Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment One of 40 patients changed treatment but all remained on brentuximab regardless of scan results Sep 09, 2023
Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies Increased risk for non-melanoma skin cancer, MDS, AML versus the general population Sep 09, 2023
Adcetris Plus Chemo Effective in HIV-Related Hodgkin Lymphoma Researchers call study "practice changing," although outside experts urge caution Aug 04, 2023
Anti-PD-1 Alone Produces Durable Responses in Relapsed/Refractory PMBCL More than 80% of responding patients remained in response at 4 years Jul 24, 2023
Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
Why Did Older Man Develop Itchy, Full-Body Rash? Here's how the medical team diagnosed and treated the rare inflammatory skin disorder Jun 22, 2023
New Bispecific Antibody Approved for Tough-to-Treat Lymphoma Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate Jun 16, 2023
Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis Patients with depression alone had the worst overall survival Jun 13, 2023
CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma The CAR T-cell therapy led to significantly longer overall survival Jun 05, 2023
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease Jun 04, 2023
What to Know About Hank Green's Hodgkin's Lymphoma Diagnosis Hodgkin's is one of the more rare lymphomas, but tends to be very treatable May 24, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
